CAPLYTA® nearly doubles remission rates in major depressive disorder when used with antidepressants, showing sustained benefits over six months in clinical studies.
11 abstracts on neuropsychiatry, including MDD and TRD, will be presented, highlighting clinical and preclinical research, AI tools, and novel therapeutic mechanisms.
